{"component": "definition", "props": {"groups": [{"size": 8, "samples": [{"hash": "i3QB3Bf2qid", "uri": "/contracts/i3QB3Bf2qid#primary-detail-equivalent", "label": "Promotion Agreement (Reliant Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "7SCcRb07DSM", "uri": "/contracts/7SCcRb07DSM#primary-detail-equivalent", "label": "Promotion Agreement (Reliant Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "jLW7pYyDEyo", "uri": "/contracts/jLW7pYyDEyo#primary-detail-equivalent", "label": "Promotion Agreement (Reliant Pharmaceuticals, Inc.)", "score": 19.0, "published": true}], "snippet": "means either (i) a First Position Detail or (ii) two and one-half (2.5) Second Position Details.", "snippet_links": [{"key": "first-position-detail", "type": "definition", "offset": [19, 40]}], "hash": "0dfbf1b0eefc9f4c02cd0887ca1dcaad", "id": 1}, {"size": 4, "samples": [{"hash": "96UGijHRglv", "uri": "/contracts/96UGijHRglv#primary-detail-equivalent", "label": "Sales and Promotional Services Agreement", "score": 31.340862423, "published": true}, {"hash": "6G0nGghKQUT", "uri": "/contracts/6G0nGghKQUT#primary-detail-equivalent", "label": "Sales and Promotional Services Agreement", "score": 31.340862423, "published": true}, {"hash": "8aBR6SSImz4", "uri": "/contracts/8aBR6SSImz4#primary-detail-equivalent", "label": "Sales and Promotional Services Agreement (Endo Pharmaceuticals Holdings Inc)", "score": 22.158110883, "published": true}], "snippet": "or \u201cPDE\u201d is calculated as 100% of Primary Details plus 50% of Secondary Details.", "snippet_links": [], "hash": "9f07e01bb154a8c9a21f9def32699a5e", "id": 2}, {"size": 4, "samples": [{"hash": "dxFQ9AbLSNu", "uri": "/contracts/dxFQ9AbLSNu#primary-detail-equivalent", "label": "Development, Licensing and Marketing Agreement", "score": 26.9438740589, "published": true}, {"hash": "aW9AsxSrIEf", "uri": "/contracts/aW9AsxSrIEf#primary-detail-equivalent", "label": "License Agreement (Adamas Pharmaceuticals Inc)", "score": 25.1724845996, "published": true}, {"hash": "gcnLpToH0SO", "uri": "/contracts/gcnLpToH0SO#primary-detail-equivalent", "label": "License Agreement (Adamas Pharmaceuticals Inc)", "score": 25.0821355236, "published": true}], "snippet": "or \u201cPDE\u201d. Primary Detail Equivalent or PDE means a primary Detail equivalent where (a) a Primary Detail has a value of 1.0 primary Detail equivalent and (b) a Secondary Detail has the value of [*] primary Detail equivalents.", "snippet_links": [{"key": "secondary-detail", "type": "definition", "offset": [159, 175]}, {"key": "the-value", "type": "clause", "offset": [180, 189]}, {"key": "primary-detail-equivalents", "type": "clause", "offset": [197, 223]}], "hash": "5a00931f4b033a0484a626b5e13ae86c", "id": 3}, {"size": 4, "samples": [{"hash": "4WUkhsiRqeu", "uri": "/contracts/4WUkhsiRqeu#primary-detail-equivalent", "label": "Development and Collaboration Agreement", "score": 31.340862423, "published": true}, {"hash": "4b0lEmIkjdr", "uri": "/contracts/4b0lEmIkjdr#primary-detail-equivalent", "label": "Development and Collaboration Agreement (Acucela Inc)", "score": 24.9589322382, "published": true}, {"hash": "bVleYhRTXlg", "uri": "/contracts/bVleYhRTXlg#primary-detail-equivalent", "label": "Development and Collaboration Agreement (Acucela Inc)", "score": 24.5071868583, "published": true}], "snippet": "means a primary Detail equivalent, where a Primary Position Detail has a value of * and a Secondary Position Detail has a value of *. A Detail below the Secondary Position shall have *.", "snippet_links": [{"key": "primary-position-detail", "type": "definition", "offset": [43, 66]}, {"key": "secondary-position-detail", "type": "definition", "offset": [90, 115]}], "hash": "55c90eef6af2ee21baa8b3d0e4af6ee2", "id": 4}, {"size": 4, "samples": [{"hash": "IoyPO9KdzH", "uri": "/contracts/IoyPO9KdzH#primary-detail-equivalent", "label": "Co Development, Co Promotion, Marketing and Licensing Agreement", "score": 26.8904859685, "published": true}, {"hash": "6bT0qoAjGPY", "uri": "/contracts/6bT0qoAjGPY#primary-detail-equivalent", "label": "Co Development, Co Promotion, Marketing and Licensing Agreement", "score": 26.8904859685, "published": true}, {"hash": "b8dDTgqsBO4", "uri": "/contracts/b8dDTgqsBO4#primary-detail-equivalent", "label": "Collaboration Agreement (Orexigen Therapeutics, Inc.)", "score": 21.8405201916, "published": true}], "snippet": "or \u201cPDE\u201d means a primary detail equivalent for the Product equal to [***] Detail or [***] Details. For the avoidance of doubt, details that are not [***] Details or [***] Details have no Primary Detail Equivalents. A \u201c[***] Detail\u201d means a detail delivered by a Sales Representative face-to-face to a contact target in which the promotional message involving the Product is [***]; and a \u201c[***] Detail\u201d means a detail delivered by a Sales Representative face-to-face to a contact target in which the promotional message involving the Product is [***]. For the avoidance of doubt, electronic and telemarketing details are not Primary Detail Equivalents.", "snippet_links": [{"key": "the-product", "type": "clause", "offset": [47, 58]}, {"key": "equal-to", "type": "definition", "offset": [59, 67]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [99, 125]}, {"key": "primary-detail-equivalents", "type": "clause", "offset": [187, 213]}, {"key": "sales-representative", "type": "definition", "offset": [262, 282]}], "hash": "e38f3b8e6defb32652bf25cad970eac6", "id": 5}, {"size": 3, "samples": [{"hash": "kwMjvBdsZKj", "uri": "/contracts/kwMjvBdsZKj#primary-detail-equivalent", "label": "Co Promotion Agreement", "score": 31.340862423, "published": true}, {"hash": "e5Db4dKJ8t4", "uri": "/contracts/e5Db4dKJ8t4#primary-detail-equivalent", "label": "Co Promotion Agreement (Auxilium Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "3To1DkoQR1Z", "uri": "/contracts/3To1DkoQR1Z#primary-detail-equivalent", "label": "Co Promotion Agreement (Oscient Pharmaceuticals Corp)", "score": 21.0, "published": true}], "snippet": "means either one (1) Primary Detail or two (2) Secondary Details conducted by a Party.", "snippet_links": [{"key": "primary-detail", "type": "definition", "offset": [21, 35]}, {"key": "by-a-party", "type": "clause", "offset": [75, 85]}], "hash": "e0a0d2f4011bf29b9aeef8850be32716", "id": 6}, {"size": 3, "samples": [{"hash": "a9lub0q6F8l", "uri": "/contracts/a9lub0q6F8l#primary-detail-equivalent", "label": "Collaboration and License Agreement", "score": 31.340862423, "published": true}, {"hash": "fy1KL448wUe", "uri": "/contracts/fy1KL448wUe#primary-detail-equivalent", "label": "Collaboration and License Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "fbffL2QHwh5", "uri": "/contracts/fbffL2QHwh5#primary-detail-equivalent", "label": "Collaboration and License Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "snippet": "or \u201cPDE\u201d shall mean (a) one Primary Product Detail or (b) [**] Secondary Product Details.", "snippet_links": [{"key": "primary-product", "type": "definition", "offset": [28, 43]}, {"key": "product-details", "type": "clause", "offset": [73, 88]}], "hash": "7372aee276c6564fe9be5c8d1bdda02b", "id": 7}, {"size": 3, "samples": [{"hash": "eYT2WzzumBP", "uri": "/contracts/eYT2WzzumBP#primary-detail-equivalent", "label": "Co Promotion Agreement", "score": 31.340862423, "published": true}, {"hash": "ejcDCvx8xOH", "uri": "/contracts/ejcDCvx8xOH#primary-detail-equivalent", "label": "Co Promotion Agreement (Amarin Corp Plc\\uk)", "score": 25.3504449008, "published": true}, {"hash": "es5gdJKRADT", "uri": "https://investor.amarincorp.com/static-files/b97bae68-d961-4b95-9241-f21825bfae48", "label": "investor.amarincorp.com", "score": 8.1704312115, "published": false}], "snippet": "or \u201cPDE\u201d means a numerical amount that scores the value of Details performed by Kowa Sales Representatives or Amarin Sales Representatives: [***].", "snippet_links": [{"key": "the-value", "type": "clause", "offset": [46, 55]}, {"key": "performed-by", "type": "clause", "offset": [67, 79]}, {"key": "sales-representatives", "type": "clause", "offset": [85, 106]}], "hash": "a5f998ba720f0dc478a3929d831a583c", "id": 8}, {"size": 3, "samples": [{"hash": "hsQN2Lvmg8a", "uri": "/contracts/hsQN2Lvmg8a#primary-detail-equivalent", "label": "Collaboration and Distribution Agreement (Forest Laboratories Inc)", "score": 23.1054072553, "published": true}], "snippet": "or \u201cPDE\u201d means (i) one Primary Detail or (ii) two Secondary Details.", "snippet_links": [{"key": "primary-detail", "type": "definition", "offset": [23, 37]}], "hash": "2f820c655c41f90037483dd9636f7c3b", "id": 9}, {"size": 2, "samples": [{"hash": "ph6ZuxS8sp", "uri": "/contracts/ph6ZuxS8sp#primary-detail-equivalent", "label": "Co Promotion Agreement (Zogenix, Inc.)", "score": 20.8186173854, "published": true}, {"hash": "eQm8ZkGWQzr", "uri": "/contracts/eQm8ZkGWQzr#primary-detail-equivalent", "label": "Co Promotion Agreement (Zogenix, Inc.)", "score": 20.6707734428, "published": true}], "snippet": "means a primary Detail equivalent for the Product equal to [***], [***], or [***]. For the avoidance of doubt, Details that are not P1 Details, P2 Details, or Co-P2 Details [***].", "snippet_links": [{"key": "the-product", "type": "clause", "offset": [38, 49]}, {"key": "equal-to", "type": "definition", "offset": [50, 58]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [83, 109]}], "hash": "1faaeff635f61b2513a11de8ca06f937", "id": 10}], "next_curs": "CmYSYGoVc35sYXdpbnNpZGVyY29udHJhY3RzckILEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIicHJpbWFyeS1kZXRhaWwtZXF1aXZhbGVudCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 49, "snippet": "means either (i) a First Position Detail or (ii) two and one-half (2.5) Second Position Details.", "title": "Primary Detail Equivalent", "id": "primary-detail-equivalent", "examples": ["Month at a rate of [***] dollars [***] ($[***]) per <strong>Primary Detail Equivalent</strong> for Agreement Year 2006 and [***] dollars [***] ($[***]) per <strong>Primary Detail Equivalent</strong> for Agreement Year 2007.", "For Agreement Years 2006 and 2007 only, Novartis shall reimburse Reliant on a monthly basis for each <strong>Primary Detail Equivalent</strong> that occurred during such [***]: Certain information on this page has been omitted and filed separately with the Commission.", "For Agreement Years 2006 and 2007 only, Novartis shall reimburse Reliant on a monthly basis for each <strong>Primary Detail Equivalent</strong> that occurred during such Month at [***].", "API shall compensate P&amp;G or P&amp;G\u2019s Affiliate for the Detailing Efforts and Non-Detailing Promotion Efforts actually undertaken within such country based on an agreed upon cost per <strong>Primary Detail Equivalent</strong> determined by reference to an average of the parties\u2019 actual cost of performing a <strong>Primary Detail Equivalent</strong>.", "For Agreement Years 2006 and 2007 only, Novartis shall reimburse Reliant on a monthly basis for each <strong>Primary Detail Equivalent</strong> that occurred during such Month at a rate of [***] dollars ($[***]) per <strong>Primary Detail Equivalent</strong> for Agreement Year 2006 and [***] dollars ($[***]) per <strong>Primary Detail Equivalent</strong> for Agreement Year 2007.", "In calculating the number of PDEs resulting from such group presentations, each Prescribing Professional participating in such presentations will be considered as one (1) <strong>Primary Detail Equivalent</strong> (PDE)."], "related": [["generic-equivalent", "Generic Equivalent", "Generic Equivalent"], ["dose-equivalent", "Dose equivalent", "Dose equivalent"], ["spousal-equivalent", "Spousal equivalent", "Spousal equivalent"], ["aluminum-equivalent", "Aluminum equivalent", "Aluminum equivalent"], ["therapeutic-equivalent", "Therapeutic equivalent", "Therapeutic equivalent"]], "related_snippets": [], "updated": "2025-07-06T21:58:29+00:00"}, "json": true, "cursor": ""}}